The low cost versions of Epclusa (sofosbuvir+velpatasvir) and Harvoni (ledipasvir+sofosbuvir) will launch in January. The most common course of therapy will be available at a list price of $24,000.
AbbVie’s Maviret (glecaprevir+pibrentasvir) and Gilead’s Vosevi (sofosbuvir+velpatasvir+voxilepravir) cover all six major hepatitis C genotypes. In patients without cirrhosis, Maviret also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback